CME Information

LEARNING OBJECTIVES
Upon completion of the activity, participants should be able to:

• Integrate new information on IPF treatment into practice as it becomes available
• Discuss timing and rationale for starting antifibrotic therapy
• Decide when to stop or switch treatment
• Discuss disease progression treatment expectations and the importance of adhering to treatment

ACTIVITY FACULTY
Kevin Flaherty, MD
Director Interstitial Lung Disease Program
Professor of Medicine
University of Michigan

Lisa H. Lancaster, MD
Director Interstitial Lung Disease Program
Professor of Medicine
Vanderbilt University

METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT

1. There are no fees for participating in and receiving credit for this activity.
2. Review the activity objectives and CME/CE information.
3. Complete the CME/CE activity
4. Complete the CME/CE evaluation/attestation form. This form provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
5. Credit documentation/reporting:
   • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.

CLICK HERE TO VIEW TECHNICAL REQUIREMENTS

ACCREDITED PROVIDER
This activity is provided by The France Foundation.

TARGET AUDIENCE
This activity is intended for pulmonologists, critical care specialists, internists, fellows, and other health care providers who manage patients with IPF.

STATEMENT OF NEED
Clinicians need practical advice about IPF treatments to improve their competence in selecting better ways to manage their patients with IPF.

ACCREDITATION STATEMENT
The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION
Physicians: The France Foundation designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURE POLICY
In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Activity Staff Disclosures
The planners, reviewers, editors, staff, CME committee, and other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures
The faculty listed below report that they have relevant financial relationships to disclose:

• Kevin Flaherty, MD, has done contract research for the University of Michigan, Boehringer Ingelheim Pharmaceuticals, Inc. and non-CE research for Bellerophon, Blade Therapeutics, Boehringer Ingelheim Pharmaceuticals, Inc., Respivant, Vindico, Roche/Genentech, and Shionogi. He has also done consulting for Arrowhead Pharmaceuticals, AstraZeneca, DevPro Biopharma, Fibrogen, Horizon, Lupin Pharmaceuticals, Pure Health, Sun Pharmaceutical, Pliant, Polarean, and United Therapeutics.
• Lisa H. Lancaster, MD, has done consulting work for AstraZeneca, Bellerophon, BMS, DevPro Biopharma, Galapagos, Genentech, Pliant, United Therapeutics, and Veracyte. She has served on a speakers bureau for Boehringer Ingelheim Pharmaceuticals, Inc., Genentech, United Therapeutics, and Veracyte. She has also participated in contract research for Biogen, Boehringer Ingelheim Pharmaceuticals, Inc., Bellerophon, BMS, Celgene, Fibrogen, Galecto, Galapagos, and Novartis, Pliant, Respivant, and Roche.

DISCLOSURE OF UNLABELED USE
TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGMENT
This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

DISCLAIMER
The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

COPYRIGHT INFORMATION
Copyright © 2021 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

• The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
• Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

PRIVACY POLICY
The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at http://www.francefoundation.com/privacy-policy.

CONTACT INFORMATION
If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.